左氧氟沙星联合头孢哌酮/舒巴坦治疗呼吸机相关肺炎的疗效评价

Assessing the Effects of Levofloxacin Combined with Cefoperazone/Sulbactam for the Treatment of Ventilator-Associated Pneumonia

目的评价左氧氟沙星联合头孢哌酮/舒巴坦治疗呼吸机相关肺炎(VAP)的有效性和安全性。方法回顾性分析左氧氟沙星联合头孢哌酮/舒巴坦治疗58例VAP的临床疗效。临床疗效评价分为痊愈、显效、无效,痊愈和显效的病例合计为有效。结果痊愈26例(44.8%),显效18例(31.1%),无效14例(24.1%),临床总有效率为75.9%。细菌培养共获55株菌株,以革兰阴性菌为主(占78.2%),细菌清除率为78.2%。不良反应发生率为5.1%。结论左氧氟沙星联合头孢哌酮/舒巴坦治疗VAP,临床疗效确切、安全性高,可作为治疗VAP的经验性用药。

Objective To evaluate the efficacy and safety of Levofloxacin combined with Cefoperazone/ Sulbactam on the patients with ventilator-associated pneumonia （VAP）. Methods The clinical effect of Levofloxacin combined with Cefoperazone/Sulbactam on ventilator-associated pneumonia in 58 paitiens with VAP were retrospectively analyzed. Results 26 patients （ 44. 8% ） were cured, 18 patients （ 31.1% ） were marked improved,and 14 patients （24. 1% ） were ineffective. The total clinical efficacy rate was 75.9%. 55 strains of bacteria were isolated,and Gram-negative bacilli were dominant pathogens（78.2% ）. The bacterial clearance rate was 78.2%. The prevalence of adverse reaction was 5.1%. Conclusion Levofloxacin combined with Cefoperazone/Sulbactam is effective and safe for patients with VAP.